-5%
Daprodustat is used to treat anemia caused by chronic kidney disease (CKD) in patients who have been on dialysis for at least 4 months. This medicine works by increasing erythropoietin (protein) to help the body make more red blood cells. It is also used to lessen or avoid the need for blood transfusion.
Available in 1 mg, 2 mg, 4 mg, 6 mg, and 8 mg tablet strengths for once-daily oral administration, with or without food. Aprodust 2 should be taken orally exactly as prescribed by the physician. Swallow the tablet whole without chewing, crushing, or breaking it.
Aprodust is indicated for the treatment of anemia due to CKD in adult patients who have been on dialysis for at least four months.
It should not be used:
- As an alternative to emergency blood transfusion
- In CKD patients not receiving dialysis
Daprodustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI). HIF-PH enzymes regulate intracellular levels of hypoxia-inducible factor (HIF), a transcription factor involved in erythropoiesis. Activation of the HIF pathway plays a key role in the body’s adaptive response to low oxygen levels by promoting red blood cell production.
By reversibly inhibiting HIF-PH enzymes, Daprodustat increases endogenous erythropoietin (EPO) production, improves regulation of iron transport proteins, and lowers hepcidin levels, which are often elevated in chronic kidney disease (CKD). These effects enhance iron availability, stimulate hemoglobin synthesis, and increase red blood cell mass.